Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.42 |
| ▸ | LGALS3 | P17931 | 5/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.41 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27490637 | 0.88 | SLC6A2 (0.54) | SLC6A2TYRLGALS8LGALS3SLC5A2 | |
| SCHEMBL27491005 | 0.86 | SLC6A2 (0.54) | SLC6A2TYRLGALS8LGALS3SLC5A2 | |
| SCHEMBL27492046 | 0.85 | SLC6A2 (0.52) | SLC6A2TYRLGALS8LGALS3SLC5A2 | |
| SCHEMBL27473226 | 0.85 | SLC5A1 (0.55) | SLC6A2TYRLGALS8LGALS3SLC5A2 | |
| SCHEMBL27473225 | 0.84 | SLC6A2 (0.54) | SLC6A2TYRLGALS8LGALS3SLC5A2 | |
| SCHEMBL27490639 | 0.83 | SLC6A2 (0.52) | SLC6A2TYRLGALS8LGALS3SLC5A2 | |
| SCHEMBL27491693 | 0.82 | SLC6A2 (0.53) | SLC6A2TYRLGALS8LGALS3SLC5A2 | |
| SCHEMBL15481400 | 0.81 | SLC6A2 (0.57) | SLC6A2TYRLGALS8LGALS3SLC5A2 | |
| SCHEMBL18523297 | 0.81 | SLC6A2 (0.57) | SLC6A2TYRLGALS8LGALS3SLC5A2 | |
| SCHEMBL14127626 | 0.80 | SLC6A2 (0.58) | SLC6A2TYRLGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045466-A1 | Progression Inhibitor For Disease Attributed To Abnormal Accumulation Of Liver Fat | SLC10A1, SLC2A2, SLC2A1 | SLC6A2 118/4885TYR 2971/4885LGALS8 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.